Article
Medicine, General & Internal
Fusae Kato, Miho Nozaki, Aki Kato, Tsutomu Yasukawa
Summary: This study used OCTA to investigate microvascular changes after intravitreal TA treatment. The results showed that TA can decrease the number of microaneurysms and increase the foveal avascular zone area.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Ophthalmology
Rei Sotani-Ogawa, Sentaro Kusuhara, Yushi Hirota, Kyung Woo Kim, Wataru Matsumiya, Wataru Ogawa, Makoto Nakamura
Summary: This pilot study aimed to evaluate the effects of STTA on glycemic control in patients with DME. The results showed that although there were no significant changes in CGM metrics, four patients developed hyperglycemia after STTA treatment.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tongtao Zhao, Hongxuan Lie, Fang Wang, Yong Liu, Xiaohong Meng, Zhengqin Yin, Shiying Li
Summary: This study compared the safety and efficacy of a modified sub-Tenon's capsule injection of triamcinolone acetonide (TA) and intravenous infusion of umbilical cord mesenchymal stem cells (UCMSCs) in treating retinitis pigmentosa combined with macular edema. Results showed that TA injection was more effective in alleviating edema and improving visual function in the short term, while UCMSC intravenous infusion showed a slower but persistent action in alleviating edema and improving visual function for a longer time. Both treatments were deemed safe for the patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Ophthalmology
Andrew Mihalache, Amin Hatamnejad, Nikhil S. Patil, Marko M. Popovic, Peter J. Kertes, Miguel Cruz-Pimentel, Rajeev H. Muni
Summary: In patients with macular edema secondary to retinal vein occlusion, high dose intravitreal triamcinolone acetonide (IVTA) showed better improvements in visual acuity and reduction in retinal thickness compared to low dose IVTA. However, high dose IVTA had a higher risk of intraocular pressure-related adverse events and cataract surgery. These differences were not observed in patients with diabetic macular edema.
Review
Medicine, General & Internal
Andrzej Grzybowski, Agne Markeviciute, Reda Zemaitiene
Summary: Macular edema is commonly caused by retinal vein occlusion and diabetes, with anti-VEGF intravitreal injections replacing laser photocoagulation as the primary treatment. However, this treatment may require frequent injections and some patients may not respond well, indicating the need for alternative therapies and potential future use of artificial intelligence in treatment selection.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Yun-Hsiang Yang, Wei-Cherng Hsu, Yi-Ting Hsieh
Summary: Anterior migration of triamcinolone acetonide after PSTA increases the risk of severe IOP elevation, with anterior subtenon migration and anterior subconjunctival migration occurring in 70.4% and 12.0% of injections respectively. Compared to those without anterior migration, patients with anterior subtenon migration had a hazard ratio of 3.307 for severe IOP elevation, while those with anterior subconjunctival migration had a hazard ratio of 5.289. Careful injection to prevent anterior migration may reduce the rate of IOP elevation after PSTA.
CURRENT EYE RESEARCH
(2021)
Article
Ophthalmology
Boushra M. Ali, Arwa M. Azmeh, Nawras M. Alhalabi
Summary: This study evaluates the feasibility of using suprachoroidal injection of Triamcinolone Acetonide (TA) as a mono-treatment for Macular Edema (ME) associated with Retinal Vein Occlusion (RVO). The results suggest that this treatment method is safe and effective in improving visual acuity and reducing central subfield thickness.
Article
Medicine, General & Internal
Farheen Tariq, Yanfen Wang, Bo Ma, Yidan He, Shu Zhang, Ling Bai
Summary: This study compared the visual and morphological effects of filtered modified 2 mg triamcinolone acetonide (TA) and 0.5 mg ranibizumab in patients with pseudophakic cystoid macular edema (PCME). The results showed that both TA and ranibizumab intravitreal injection can improve BCVA and reduce CMT in patients with PCME. The TA group showed a trend towards greater improvement, especially in patients with diabetes mellitus.
FRONTIERS IN MEDICINE
(2022)
Article
Ophthalmology
Ahmed Abdelshafy Tabl, Tarek Tawfik Soliman, Mohamed Anany Elsayed, Marwa Abdelshafy Tabl
Summary: This study compared the efficacy and safety of suprachoroidal and intravitreal injection of triamcinolone acetonide for pseudophakic patients with refractory diabetic macular edema. The results showed that both treatments were effective in reducing central foveal thickness and improving visual acuity, but intravitreal injection had a higher recurrence rate and elevated intraocular pressure.
JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Pharmacology & Pharmacy
Dadi A. Srinivasarao, S. Sreenivasa Reddy, G. Bhanuprakash Reddy, Dhirendra S. Katti
Summary: A polymeric nanoparticle delivery system was fabricated for simultaneous treatment of anterior and posterior eye diseases. In vivo efficacy studies in rat models showed that administration of PDTC and TA reduced oxidative stress in the lens and ameliorated DR complications in the retina. This approach may be useful for treating diabetic cataract and DR simultaneously.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Pharmacology & Pharmacy
Maria Lina Formica, Hamoudi Ghassan Awde Alfonso, Alejandro Javier Paredes, Maria Elisa Melian, Nahuel Matias Camacho, Ricardo Faccio, Luis Ignacio Tartara, Santiago Daniel Palma
Summary: Triamcinolone acetonide nanocrystals (TA-NC) were obtained to improve ocular corticosteroid therapy. Self-dispersible TA-NC with a average particle size of 257 +/- 30 nm and a zeta potential of -25 +/- 3 mV were prepared by bead milling technique and spray-drying. In vivo evaluation in an ocular model showed that self-dispersible TA-NC alleviated the inflammatory response in rabbit eyes. Self-dispersible TA-NC are a promising approach for ocular disorders.
Article
Ophthalmology
Steven Yeh, Christopher R. Henry, Barry Kapik, Thomas A. Ciulla
Summary: The results of this study demonstrate the effectiveness and tolerability of SCS-TA in the treatment of macular edema secondary to noninfectious uveitis.
OPHTHALMOLOGY AND THERAPY
(2023)
Article
Chemistry, Medicinal
Dan Lin, Jiajiang Hu, Ke Wu, Kemi Feng, Xia Zhao, Qingqing Lu, Mingxue Ren, Junlin Cao, Ruru Liu, Mali Dai, Kaihui Nan, Yuqin Wang
Summary: The combination therapy of intravitreal anti-VEGF and sub-Tenon triamcinolone acetonide injection is more effective than triamcinolone acetonide injection alone in reducing uveitic macular edema and restoring visual acuity. The addition of anti-VEGF does not increase the risk of steroid-induced elevation of intraocular pressure over a period of 6 months.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Health Care Sciences & Services
Linan Zhang, Xiaolong Chen
Summary: The combined therapy of IVTA + laser is similar to IVTA alone but superior to laser alone for early treatment of DME. However, in long-term treatment, the efficacy of IVTA + laser is similar to IVTA alone or laser alone, with a better therapeutic effect achieved if IVTA is administered before laser treatment.
ANNALS OF PALLIATIVE MEDICINE
(2021)
Article
Ophthalmology
Mahmoud Mohammed Ahmed Ali Khalil, Hosam Othman Mansour, Ahmed Mohamed Raafat Tawfik, Ahmed Gomaa Elmahdy
Summary: The study indicated that combining cataract surgery with drug injections can effectively prevent further progression in CMT for patients with diabetic macular edema following cataract surgery.